MR2938 relieves DSS-induced colitis in mice through inhibiting NF-κB signaling and improving epithelial barrier.

ABSTRACT: Damage to the epithelial barrier is among key processes contributing to initiation and chronic inflammation in inflammatory bowel diseases (IBD). Only management therapy exists for IBD (e.g., anti-inflammatory and immunomodulatory agents, JAK/STAT inhibitors), and while novel therapeutic approaches have shown great potential, issues remain including route of administration, development of resistance to therapy and toxicity. Thus, novel small molecule inhibitors which can alleviate colonic inflammation and restore intestinal barrier functions are needed. Our previous study identified a new quinazolinone derivative MR2938, inspired by marine natural product penipanoid C, displaying impressive anti-inflammatory effects. In vivo efficacy study indicated that MR2938 had a dose-dependent effect

SUBMITTER: Lv L 

PROVIDER: S-EPMC12662929 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature